Go Pro
→ ALT SL: New Patent Reveals Elon Musk’s Next Breakthrough: M.A.G.I. (From Brownstone Research) (Ad)tc pixel Free CRBP Stock Alerts

Corbus Pharmaceuticals (CRBP) Financials

Corbus Pharmaceuticals logo
$9.05 +0.13 (+1.46%)
Closing price 04:00 PM Eastern
Extended Trading
$8.99 -0.06 (-0.61%)
As of 05:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Corbus Pharmaceuticals

Annual Income Statements for Corbus Pharmaceuticals

This table shows Corbus Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -8.85 -20 -32 -56 -71 -100 -46 -42 -44 -40 -79
Consolidated Net Income / (Loss)		 -8.85 -20 -32 -56 -71 -223 -91 -85 -89 -80 -157
Net Income / (Loss) Continuing Operations		 -8.85 -20 -32 -56 -71 -100 -46 -85 -89 -80 -157
Total Pre-Tax Income 		-8.85 -20 -32 -56 -71 -111 -46 -85 -89 -80 -157
Total Operating Income		 -8.85 -20 -33 -57 -77 -123 -56 -40 -45 -49 -85
Total Gross Profit		 0.65 1.91 2.44 4.82 36 3.94 0.88 0.00 1.64 6.31 5.53
Total Revenue		 0.65 1.91 2.44 4.82 36 3.94 0.88 0.00 1.64 6.31 5.53
Operating Revenue		 0.65 1.91 2.44 4.82 36 3.94 0.88 0.00 1.64 6.31 5.53
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 9.50 22 35 62 113 127 57 80 90 97 171
Selling, General & Admin Expense		 3.61 6.46 8.96 13 24 28 20 19 14 16 15
Research & Development Expense		 5.89 15 26 49 90 98 36 16 31 32 70
Other Operating Expenses / (Income)		 - - - - - - - 40 45 49 85
Other Special Charges / (Income)		 - - - - - - 0.00 5.00 0.00 0.00 0.00
Total Other Income / (Expense), net		 0.00 -0.01 0.14 1.08 5.65 12 10 -5.09 -0.56 11 7.93
Interest Expense		 - - - - -1.23 1.03 1.83 2.13 3.86 1.87 0.00
Other Income / (Expense), net		 0.00 -0.01 -0.04 0.09 4.42 13 12 -2.95 3.30 13 7.93
Basic Earnings per Share		 ($0.28) ($0.49) ($0.65) ($0.98) ($1.12) ($1.42) ($11.15) ($10.15) ($10.31) ($3.68) ($5.90)
Weighted Average Basic Shares Outstanding		 31.35M 41.14M 50.18M 57.00M 63.90M 78.13M 4.09M 4.17M 4.33M 10.92M 13.32M
Diluted Earnings per Share		 ($0.28) ($0.49) ($0.65) ($0.98) ($1.12) ($1.42) ($11.15) ($10.15) ($10.31) ($3.68) ($5.90)
Weighted Average Diluted Shares Outstanding		 31.35M 41.14M 50.18M 57.00M 63.90M 78.13M 4.09M 4.17M 4.33M 10.92M 13.32M
Weighted Average Basic & Diluted Shares Outstanding		 31.35M 41.14M 50.18M 57.00M 63.90M 78.13M 122.99M 4.17M 10.49M 12.23M 17.74M

Quarterly Income Statements for Corbus Pharmaceuticals

This table shows Corbus Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -10 -8.01 -7.93 -10 -16 -6.41 -17 -18 -23 -21 -23
Consolidated Net Income / (Loss)		 -20 -16 -14 -20 -28 -19 -34 -35 -47 -41 -46
Net Income / (Loss) Continuing Operations		 -20 -16 -7.93 -20 -16 -37 -34 -35 -47 -41 -46
Total Pre-Tax Income 		-20 -16 -7.93 -20 -16 -37 -34 -35 -47 -41 -46
Total Operating Income		 -9.49 -10 -9.62 -11 -16 -13 -20 -19 -24 -22 -24
Total Gross Profit		 0.00 1.64 0.00 1.60 0.00 4.71 1.68 1.31 1.13 1.41 1.40
Total Revenue		 0.00 1.64 0.00 1.60 0.00 4.71 1.68 1.31 1.13 1.41 1.40
Operating Revenue		 - - - 1.60 - - 1.68 1.31 1.13 1.41 1.40
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 19 20 9.62 22 16 50 40 38 49 44 49
Selling, General & Admin Expense		 2.94 3.12 3.86 4.12 4.70 3.82 4.13 3.97 3.56 3.56 4.49
Research & Development Expense		 6.55 6.98 5.76 6.87 11 8.79 16 15 21 18 20
Other Operating Expenses / (Income)		 9.49 10 - 11 - - 20 19 24 22 24
Total Other Income / (Expense), net		 -1.11 2.53 1.70 0.32 -0.18 8.91 3.86 1.65 1.06 1.36 1.16
Interest Expense		 0.76 1.64 0.84 0.65 0.38 - 0.00 0.00 0.00 - 0.00
Other Income / (Expense), net		 -0.35 4.17 2.54 0.98 0.20 8.91 3.86 1.65 1.06 1.36 1.16
Basic Earnings per Share		 ($2.27) ($1.85) ($0.83) ($0.90) ($1.15) ($0.59) ($1.39) ($1.44) ($1.90) ($1.17) ($1.23)
Weighted Average Basic Shares Outstanding		 4.42M 4.33M 8.31M 11.05M 12.01M 10.92M 12.20M 12.24M 12.31M 13.32M 18.71M
Diluted Earnings per Share		 ($2.27) ($1.85) ($0.83) ($0.90) ($1.15) ($0.59) ($1.39) ($1.44) ($1.90) ($1.17) ($1.23)
Weighted Average Diluted Shares Outstanding		 4.42M 4.33M 8.31M 11.05M 12.01M 10.92M 12.20M 12.24M 12.31M 13.32M 18.71M
Weighted Average Basic & Diluted Shares Outstanding		 4.42M 10.49M 10.69M 12.04M 12.18M 12.23M 12.24M 12.26M 17.55M 17.74M 18.53M

Annual Cash Flow Statements for Corbus Pharmaceuticals

This table details how cash moves in and out of Corbus Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 6.10 2.82 48 -21 -10.00 55 -61 -8.00 -3.28 3.47 11
Net Cash From Operating Activities		 -4.62 -14 -28 -30 -46 -100 -48 -38 -36 -42 -64
Net Cash From Continuing Operating Activities		 -4.62 -14 -28 -30 -46 -100 -48 -38 -36 -42 -64
Net Income / (Loss) Continuing Operations		 -8.85 -20 -32 -56 -71 -111 -46 -42 -45 -40 -79
Consolidated Net Income / (Loss)		 -8.85 -20 -32 -56 -71 -111 -46 -42 -45 -40 -79
Depreciation Expense		 0.04 0.09 0.26 0.49 0.74 1.12 1.00 0.76 0.64 0.59 0.23
Amortization Expense		 - - - - 0.49 0.86 2.04 0.87 0.32 -2.93 -1.37
Non-Cash Adjustments To Reconcile Net Income		 1.15 3.18 5.69 8.10 9.35 14 12 7.20 4.27 7.26 7.11
Changes in Operating Assets and Liabilities, net		 3.03 3.16 -1.32 17 15 -4.27 -17 -4.02 3.27 -6.46 8.07
Net Cash From Investing Activities		 -0.11 -0.35 -0.71 -2.30 -2.74 -0.48 -73 30 36 -121 -1.64
Net Cash From Continuing Investing Activities		 -0.11 -0.35 -0.71 -2.30 -2.74 -0.48 -73 30 36 -121 -1.64
Purchase of Property, Plant & Equipment		 -0.11 -0.35 -0.71 -2.30 -2.74 -0.48 -0.05 -0.01 0.00 0.00 -0.01
Purchase of Investments		 - - - - - 0.00 -87 -86 -34 -181 -163
Sale and/or Maturity of Investments		 - - - - - 0.00 14 116 70 59 161
Net Cash From Financing Activities		 11 17 76 11 38 155 61 -0.53 -2.82 167 77
Net Cash From Continuing Financing Activities		 11 17 76 11 38 155 61 -0.53 -2.82 167 77
Repayment of Debt		 -0.19 -0.24 -0.36 -0.43 -0.61 -0.95 -0.93 -2.37 -3.25 -15 0.00
Issuance of Common Equity		 11 17 79 12 41 142 63 0.00 0.05 182 77
Cash Interest Paid		 0.00 0.01 0.01 0.01 0.03 0.63 1.74 1.97 2.61 2.82 0.00

Quarterly Cash Flow Statements for Corbus Pharmaceuticals

This table details how cash moves in and out of Corbus Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 2.90 2.48 0.38 9.58 -4.26 -2.23 1.70 1.14 6.94 1.51 -3.12
Net Cash From Operating Activities		 -7.18 -6.01 -7.97 -8.94 -14 -11 -16 -17 -16 -16 -26
Net Cash From Continuing Operating Activities		 -7.18 -6.01 -7.92 -8.99 -14 -11 -16 -17 -16 -16 -26
Net Income / (Loss) Continuing Operations		 -10 -8.02 -6.90 -10.00 -14 -9.53 -17 -18 -23 -21 -23
Consolidated Net Income / (Loss)		 -10 -8.02 -6.90 -10.00 -14 -9.53 -17 -18 -23 -21 -23
Depreciation Expense		 0.15 0.15 0.15 0.15 0.15 0.13 0.08 0.05 0.05 0.05 0.05
Amortization Expense		 0.06 0.11 -0.72 -0.83 -0.56 -0.83 -0.20 -0.62 -0.05 -0.69 -0.35
Non-Cash Adjustments To Reconcile Net Income		 1.04 0.98 1.21 1.47 2.51 2.08 1.68 1.78 1.90 1.72 2.00
Changes in Operating Assets and Liabilities, net		 1.62 0.77 -1.66 0.22 -2.26 -2.75 -1.00 -0.14 5.90 3.56 -4.31
Net Cash From Investing Activities		 11 10 -98 -16 -15 8.73 18 18 20 -57 22
Net Cash From Continuing Investing Activities		 11 10 -98 -16 -15 8.73 18 18 20 -57 22
Purchase of Property, Plant & Equipment		 - - - - - - 0.00 - - - -0.01
Purchase of Investments		 -6.63 -3.33 -106 -25 -39 -11 -38 -18 -18 -90 -11
Sale and/or Maturity of Investments		 18 14 7.66 8.39 23 20 56 35 37 33 33
Net Cash From Financing Activities		 -0.82 -1.91 107 35 25 -0.01 0.00 - 2.85 75 0.00
Net Cash From Continuing Financing Activities		 -0.82 -1.91 107 35 25 -0.01 0.00 - 2.85 75 0.00
Repayment of Debt		 -0.74 -2.20 -2.32 -2.27 -11 - 0.00 - - - 0.00
Issuance of Common Equity		 -0.08 -0.07 109 37 36 -0.01 0.00 - 2.85 75 0.00
Cash Interest Paid		 0.66 0.62 0.55 0.44 1.83 - 0.00 - - - 0.00

Annual Balance Sheets for Corbus Pharmaceuticals

This table presents Corbus Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 13 18 67 47 49 102 108 66 28 156 168
Total Current Assets		 13 17 66 44 38 92 100 60 24 153 167
Cash & Equivalents		 12 15 63 42 32 85 25 17 14 17 28
Restricted Cash		 0.00 0.15 0.16 - 0.00 0.35 0.19 0.19 0.19 0.29 0.67
Short-Term Investments		 - - - - - - 73 42 7.18 132 135
Prepaid Expenses		 0.38 0.93 2.81 2.49 3.72 3.71 2.37 0.79 2.45 3.63 3.02
Plant, Property, & Equipment, net		 0.12 0.44 1.43 2.71 5.08 4.07 2.39 1.61 0.97 0.39 0.16
Total Noncurrent Assets		 0.04 0.05 0.04 0.04 5.90 6.15 5.13 4.52 3.75 2.52 1.08
Other Noncurrent Operating Assets		 - 0.00 0.04 0.04 5.90 6.15 5.13 4.52 3.75 2.52 1.08
Total Liabilities & Shareholders' Equity		 13 18 67 47 49 102 108 66 28 156 168
Total Liabilities		 3.89 8.97 9.19 19 43 57 39 33 35 13 21
Total Current Liabilities		 3.63 8.90 8.20 18 35 32 17 13 32 12 21
Accounts Payable		 1.31 3.42 3.13 6.35 11 7.38 1.78 2.17 3.18 4.79 2.22
Accrued Expenses		 0.56 3.26 4.74 9.85 22 22 10 6.00 11 5.43 17
Other Current Liabilities		 - - - 0.00 0.60 1.80 1.27 1.32 17 1.61 1.63
Total Noncurrent Liabilities		 0.26 0.07 0.99 1.38 8.10 25 22 21 3.28 1.63 0.00
Other Noncurrent Operating Liabilities		 0.00 0.00 0.00 0.00 8.10 7.09 5.98 0.02 0.04 1.63 0.00
Total Equity & Noncontrolling Interests		 8.99 8.92 58 28 6.16 45 69 33 -6.91 142 148
Total Preferred & Common Equity		 8.99 8.92 58 28 6.16 45 69 33 -6.91 142 148
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 8.99 8.92 58 28 6.16 45 69 33 -6.91 142 148
Common Stock		 22 42 123 149 199 349 419 425 430 619 703
Retained Earnings		 -13 -33 -66 -121 -193 -304 -350 -392 -437 -477 -555
Accumulated Other Comprehensive Income / (Loss)		 - - - - - 0.00 -0.06 -0.13 -0.00 0.04 -0.05

Quarterly Balance Sheets for Corbus Pharmaceuticals

This table presents Corbus Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 36 126 152 164 140 125 110 144
Total Current Assets		 31 122 148 161 137 123 108 144
Cash & Equivalents		 11 14 24 19 19 20 27 26
Restricted Cash		 0.19 0.28 0.29 0.29 0.29 0.29 0.29 0.39
Short-Term Investments		 17 106 123 140 114 97 77 113
Prepaid Expenses		 2.28 1.31 1.00 1.24 4.29 5.95 3.30 4.96
Plant, Property, & Equipment, net		 1.12 0.82 0.67 0.52 0.30 0.25 0.20 0.12
Total Noncurrent Assets		 3.96 3.23 3.00 2.76 2.27 2.01 1.74 0.80
Other Noncurrent Operating Assets		 3.96 3.23 3.00 2.76 2.27 2.01 1.74 0.80
Total Liabilities & Shareholders' Equity		 36 126 152 164 140 125 110 144
Total Liabilities		 36 29 26 14 13 14 17 18
Total Current Liabilities		 32 26 24 12 12 13 17 18
Accounts Payable		 4.71 2.08 1.15 2.89 4.07 3.99 2.74 0.44
Accrued Expenses		 7.55 9.40 10 7.18 5.90 7.65 13 16
Other Current Liabilities		 1.43 1.49 12 1.56 1.65 1.70 1.74 1.21
Total Noncurrent Liabilities		 4.43 2.86 2.46 2.05 1.21 0.76 0.31 0.00
Capital Lease Obligations		 3.61 2.86 2.46 2.05 1.21 0.76 0.31 0.00
Total Equity & Noncontrolling Interests		 0.31 97 126 150 127 111 92 126
Total Preferred & Common Equity		 0.31 97 126 150 127 111 92 126
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 0.31 97 126 150 127 111 92 126
Common Stock		 429 541 580 618 621 623 627 705
Retained Earnings		 -429 -444 -454 -467 -494 -512 -535 -578
Accumulated Other Comprehensive Income / (Loss)		 -0.01 -0.33 -0.39 0.21 -0.02 -0.04 -0.00 -0.16

Annual Metrics And Ratios for Corbus Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Corbus Pharmaceuticals' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 37,605,134.00 44,437,673.00 54,873,010.00 57,237,496.00 64,672,893.00 84,037,239.00 125,230,881.00 125,280,881.00 4,423,683.00 12,179,482.00 17,553,037.00
DEI Adjusted Shares Outstanding		 1,253,504.00 1,481,256.00 1,829,100.00 1,907,917.00 2,155,763.00 2,801,241.00 4,174,363.00 4,176,029.00 4,423,683.00 12,179,482.00 17,553,037.00
DEI Earnings Per Adjusted Shares Outstanding		 -7.06 -13.50 -17.73 -29.18 -33.15 -35.60 -10.93 -10.17 -10.03 -3.30 -4.48
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 194.80% 27.66% 97.62% 649.51% -89.11% -77.61% -100.00% 0.00% 285.76% -12.38%
EBITDA Growth		 -234.62% -126.07% -62.46% -73.61% -27.23% -51.51% 62.34% -0.95% 0.82% 5.83% -104.24%
EBIT Growth		 -234.96% -125.94% -63.03% -73.76% -28.29% -51.68% 60.26% 2.33% 2.35% 13.60% -114.35%
NOPAT Growth		 -234.46% -125.73% -62.94% -74.27% -35.87% -59.28% 54.41% 28.85% -13.16% -8.08% -75.10%
Net Income Growth		 -248.39% -125.95% -62.12% -71.71% -28.35% -211.44% 58.98% 7.22% -5.33% 9.85% -95.32%
EPS Growth		 -115.38% -75.00% -32.65% -50.77% -14.29% -26.79% 58.98% 7.22% -1.58% 64.31% -60.33%
Operating Cash Flow Growth		 -95.86% -193.44% -104.82% -8.17% -52.06% -118.03% 51.66% 22.08% 3.85% -15.77% -54.31%
Free Cash Flow Firm Growth		 -75.43% -246.27% -115.90% -25.84% -40.99% -107.23% 41.90% 33.25% 71.96% -433.43% 2.80%
Invested Capital Growth		 -1,099.63% -85.93% 23.68% -201.96% -79.60% 12.36% 57.58% 71.94% -844.26% 71.72% -137.55%
Revenue Q/Q Growth		 128.23% 0.60% -13.34% 66.57% 1.82% -32.73% -42.74% 0.00% 0.00% 95.02% -37.38%
EBITDA Q/Q Growth		 -16.18% -34.06% -11.06% -13.39% -6.66% 12.10% -2.87% -9.68% 13.59% 3.23% -27.35%
EBIT Q/Q Growth		 -16.27% -33.97% -11.10% -13.47% -7.50% 11.77% -4.65% -6.20% 13.35% 5.83% -27.96%
NOPAT Q/Q Growth		 -16.31% -34.01% -11.24% -13.45% -14.22% 4.94% 16.19% -2.05% 1.51% -5.41% -12.33%
Net Income Q/Q Growth		 -16.27% -33.98% -10.66% -13.48% -14.92% -35.58% 40.56% -17.01% 17.53% -3.90% -16.33%
EPS Q/Q Growth		 0.00% -32.43% -3.17% -11.36% -9.80% 10.69% 40.56% -17.01% 3.73% -6.05% -12.60%
Operating Cash Flow Q/Q Growth		 8.69% -51.23% -15.05% -19.71% -22.83% 4.17% 15.03% 5.65% 3.85% -13.39% -8.37%
Free Cash Flow Firm Q/Q Growth		 0.00% -68.14% -12.86% -12.69% -23.34% -10.60% 27.17% 9.14% 61.40% -59.37% -3.61%
Invested Capital Q/Q Growth		 -60.35% -3.80% 4.92% -8.14% 1.47% 38.05% 15.10% -1,202.85% -241.93% 2.56% -39.13%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -1,358.42% -1,041.71% -1,325.68% -1,164.62% -197.69% -2,749.53% -4,624.20% 0.00% -2,495.35% -609.14% -1,419.80%
Operating Margin		 -1,365.51% -1,045.56% -1,334.44% -1,176.78% -213.33% -3,119.20% -6,350.09% 0.00% -2,755.38% -772.00% -1,542.68%
EBIT Margin		 -1,365.20% -1,046.30% -1,336.15% -1,174.86% -201.09% -2,799.96% -4,968.78% 0.00% -2,553.97% -572.02% -1,399.31%
Profit (Net Income) Margin		 -1,365.05% -1,046.27% -1,328.65% -1,154.48% -197.69% -5,652.17% -10,352.77% 0.00% -5,452.81% -1,274.25% -2,840.40%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 200.00% 200.00% 99.92% 100.14% 100.04% 99.94%
Interest Burden Percent		 99.99% 100.00% 99.44% 98.27% 98.31% 100.93% 104.18% 198.08% 213.20% 222.66% 203.10%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -119.22% -223.40% -97.21% -130.52% -424.29% -865.36% -159.61% -165.91% -683.98% -118.68% -108.35%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -90.90% -130.02% -76.84% -99.42% -151.21% -145.59% -41.72% 0.00% -88.35% -39.21% -47.76%
Return on Assets (ROA)		 -90.89% -130.02% -76.41% -97.70% -148.66% -293.90% -86.92% 0.00% -188.63% -87.34% -96.94%
Return on Common Equity (ROCE)		 -119.22% -223.40% -97.21% -130.52% -424.29% -865.36% -159.61% -165.91% -683.98% -118.68% -108.35%
Return on Equity Simple (ROE_SIMPLE)		 -98.51% -224.22% -56.11% -202.27% -1,160.42% -491.53% -132.08% -256.73% 1,291.93% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -6.20 -14 -23 -40 -54 -86 -39 -28 -32 -34 -60
NOPAT Margin		 -955.85% -731.89% -934.10% -823.75% -149.33% -2,183.44% -4,445.06% 0.00% -1,928.77% -540.40% -1,079.87%
Net Nonoperating Expense Percent (NNEP)		 -28.93% -44.29% -24.91% -30.75% -48.32% -278.60% -71.66% -99.73% -216.99% -55.50% -62.15%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - 937.73% -23.95% -40.49%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 557.30% 337.95% 367.35% 268.67% 65.42% 723.36% 2,316.58% 0.00% 850.24% 261.43% 275.14%
R&D to Revenue		 908.21% 807.60% 1,067.09% 1,008.11% 247.91% 2,495.85% 4,133.50% 0.00% 1,905.13% 510.57% 1,267.54%
Operating Expenses to Revenue		 1,465.51% 1,145.56% 1,434.44% 1,276.78% 313.33% 3,219.20% 6,450.09% 0.00% 5,510.76% 1,544.00% 3,085.35%
Earnings before Interest and Taxes (EBIT)		 -8.85 -20 -33 -57 -73 -110 -44 -43 -42 -36 -77
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -8.81 -20 -32 -56 -71 -108 -41 -41 -41 -38 -79
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 6.91 42.10 6.74 12.14 57.35 2.32 1.12 0.42 0.00 1.01 0.97
Price to Tangible Book Value (P/TBV)		 6.91 42.10 6.74 12.14 57.35 2.32 1.12 0.42 0.00 1.01 0.97
Price to Revenue (P/Rev)		 95.70 196.45 159.66 69.32 9.77 26.68 87.45 0.00 16.33 22.77 25.84
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 76.92 188.67 134.10 60.74 8.91 9.65 0.00 0.00 5.60 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.02 0.03 0.01 0.01 0.12 0.41 0.28 0.72 -0.51 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.40 0.23 0.63 -0.47 0.00 0.00
Financial Leverage		 -1.24 -1.52 -1.16 -1.22 -2.15 -1.91 -1.27 -1.12 -2.04 -1.23 -1.08
Leverage Ratio		 1.31 1.72 1.27 1.34 2.85 2.94 1.84 1.70 3.63 1.36 1.12
Compound Leverage Factor		 1.31 1.72 1.27 1.31 2.81 2.97 1.91 3.38 7.73 3.03 2.27
Debt to Total Capital		 1.77% 2.96% 0.57% 1.41% 10.89% 29.27% 22.00% 41.92% -105.20% 0.00% 0.00%
Short-Term Debt to Total Capital		 1.77% 2.96% 0.57% 1.41% 10.89% 1.11% 4.36% 5.54% -8.95% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 28.16% 17.65% 36.37% -96.26% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 98.23% 97.04% 99.43% 98.59% 89.11% 70.73% 78.00% 58.08% 205.20% 100.00% 100.00%
Debt to EBITDA		 -0.02 -0.01 -0.01 -0.01 -0.01 -0.17 -0.48 -0.58 -0.09 0.00 0.00
Net Debt to EBITDA		 1.38 0.75 1.93 0.74 0.43 0.62 1.92 0.86 0.43 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -0.17 -0.38 -0.50 -0.08 0.00 0.00
Debt to NOPAT		 -0.03 -0.02 -0.01 -0.01 -0.01 -0.22 -0.50 -0.85 -0.11 0.00 0.00
Net Debt to NOPAT		 1.96 1.06 2.74 1.04 0.57 0.78 2.00 1.28 0.56 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -0.21 -0.40 -0.74 -0.10 0.00 0.00
Altman Z-Score		 6.75 19.50 23.51 3.48 -4.63 -5.87 -3.75 -9.30 -26.34 2.49 -0.92
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.50 1.96 7.98 2.45 1.09 2.89 5.89 4.76 0.74 12.94 8.07
Quick Ratio		 3.40 1.68 7.62 2.31 0.91 2.68 5.74 4.68 0.66 12.61 7.89
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -3.24 -11 -24 -30 -43 -89 -52 -35 -9.68 -52 -50
Operating Cash Flow to CapEx		 -4,055.55% -3,844.19% -3,929.25% -1,307.04% -1,667.09% -20,575.35% -159,169.19% -701,896.34% 0.00% 0.00% -921,300.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -86.58 -28.26 -16.19 -2.51 -27.59 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -96.94 -26.32 -17.61 -9.36 -22.33 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -97.41 -26.34 -17.61 -9.36 -22.33 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.07 0.12 0.06 0.08 0.75 0.05 0.01 0.00 0.03 0.07 0.03
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 7.28 6.83 2.61 2.33 9.28 0.86 0.27 0.00 1.26 9.29 20.33
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -3.23 -6.00 -4.58 -14 -25 -22 -9.23 -2.59 -24 -6.92 -16
Invested Capital Turnover		 -0.37 -0.41 -0.46 -0.52 -1.87 -0.17 -0.06 0.00 -0.12 -0.40 -0.47
Increase / (Decrease) in Invested Capital		 -2.96 -2.77 1.42 -9.25 -11 3.07 13 6.64 -22 18 -9.52
Enterprise Value (EV)		 50 361 327 293 322 38 -1.24 -22 9.16 -5.63 -21
Market Capitalization		 62 375 390 334 353 105 77 14 27 144 143
Book Value per Share		 $0.24 $0.20 $1.05 $0.48 $0.10 $0.54 $0.55 $0.26 ($1.56) $11.69 $8.40
Tangible Book Value per Share		 $0.24 $0.20 $1.05 $0.48 $0.10 $0.54 $0.55 $0.26 ($1.56) $11.69 $8.40
Total Capital		 9.15 9.19 58 28 6.91 64 89 57 -3.37 142 148
Total Debt		 0.16 0.27 0.33 0.39 0.75 19 19 24 3.54 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 18 16 21 3.24 0.00 0.00
Net Debt		 -12 -15 -62 -41 -31 -67 -78 -36 -18 -149 -164
Capital Expenditures (CapEx)		 0.11 0.35 0.71 2.30 2.74 0.48 0.03 0.01 0.00 0.00 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.09 -6.37 -5.06 -15 -28 -25 -11 -8.70 -29 -8.19 -18
Debt-free Net Working Capital (DFNWC)		 9.25 8.78 58 27 4.02 61 87 51 -8.05 141 146
Net Working Capital (NWC)		 9.08 8.50 57 26 3.27 60 83 48 -8.35 141 146
Net Nonoperating Expense (NNE)		 2.65 6.01 9.63 16 17 137 52 57 58 46 97
Net Nonoperating Obligations (NNO)		 -12 -15 -62 -41 -31 -67 -78 -36 -18 -149 -164
Total Depreciation and Amortization (D&A)		 0.04 0.09 0.26 0.49 1.23 1.99 3.04 1.63 0.96 -2.34 -1.13
Debt-free, Cash-free Net Working Capital to Revenue		 -476.80% -333.06% -207.51% -315.27% -76.72% -632.34% -1,222.77% 0.00% -1,781.48% -129.76% -319.66%
Debt-free Net Working Capital to Revenue		 1,426.13% 459.14% 2,361.82% 550.47% 11.12% 1,546.44% 9,873.87% 0.00% -491.87% 2,236.70% 2,644.88%
Net Working Capital to Revenue		 1,401.14% 444.92% 2,348.18% 542.30% 9.04% 1,528.40% 9,435.93% 0.00% -510.27% 2,236.70% 2,644.88%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($8.40) ($14.70) ($19.50) ($29.40) ($33.60) ($42.60) ($11.10) ($10.15) ($10.31) ($3.68) ($5.90)
Adjusted Weighted Average Basic Shares Outstanding		 1.25M 1.62M 1.90M 2.15M 2.42M 4.16M 4.17M 4.17M 4.33M 10.92M 13.32M
Adjusted Diluted Earnings per Share		 ($8.40) ($14.70) ($19.50) ($29.40) ($33.60) ($42.60) ($11.10) ($10.15) ($10.31) ($3.68) ($5.90)
Adjusted Weighted Average Diluted Shares Outstanding		 1.25M 1.62M 1.90M 2.15M 2.42M 4.16M 4.17M 4.17M 4.33M 10.92M 13.32M
Adjusted Basic & Diluted Earnings per Share		 ($8.40) ($14.70) ($19.50) ($29.40) ($33.60) ($42.60) ($11.10) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.05M 1.37M 1.67M 1.90M 2.13M 2.60M 4.10M 4.17M 10.49M 12.23M 17.74M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.20 -14 -23 -40 -54 -86 -39 -24 -32 -34 -60
Normalized NOPAT Margin		 -955.85% -731.89% -934.10% -823.75% -149.33% -2,183.44% -4,445.06% 0.00% -1,928.77% -540.40% -1,079.87%
Pre Tax Income Margin		 -1,365.05% -1,046.27% -1,328.65% -1,154.48% -197.69% -2,826.08% -5,176.38% 0.00% -5,445.17% -1,273.68% -2,841.99%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -107.20 -23.93 -20.07 -10.83 -19.28 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -83.60 -21.41 -13.08 -8.18 -18.22 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -107.67 -23.95 -20.07 -10.83 -19.28 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -84.07 -21.43 -13.08 -8.18 -18.22 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -5.75% -0.32% -9.07% -1.24% -3.60% -2.71% -1.99% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Corbus Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Corbus Pharmaceuticals' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 4,423,683.00 4,423,683.00 10,493,108.00 10,686,693.00 12,043,940.00 12,179,482.00 12,232,228.00 12,236,767.00 12,255,225.00 17,553,037.00 17,736,464.00
DEI Adjusted Shares Outstanding		 4,423,683.00 4,423,683.00 10,493,108.00 10,686,693.00 12,043,940.00 12,179,482.00 12,232,228.00 12,236,767.00 12,255,225.00 17,553,037.00 17,736,464.00
DEI Earnings Per Adjusted Shares Outstanding		 -2.27 -1.81 -0.76 -0.95 -1.30 -0.53 -1.40 -1.45 -1.90 -1.18 -1.31
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 187.96% 0.00% -17.88% 0.00% -70.07% -16.60%
EBITDA Growth		 -7.19% 53.09% 55.68% -29.59% -63.15% 22.64% -109.52% -69.08% -48.67% -384.32% -46.11%
EBIT Growth		 -10.21% 52.07% 59.40% -17.00% -55.55% 37.70% -124.61% -74.79% -52.60% -457.77% -45.38%
NOPAT Growth		 -15.97% 6.42% 44.37% -34.18% -63.42% -24.75% -105.50% -74.30% -57.48% -74.26% -22.90%
Net Income Growth		 -14.48% 54.17% 61.12% -13.81% -37.10% -18.80% -146.09% -76.67% -69.35% -115.69% -35.29%
EPS Growth		 -7.58% 29.92% 80.42% 56.10% 49.34% 68.11% -67.47% -60.00% -65.22% -98.31% 11.51%
Operating Cash Flow Growth		 0.95% 19.41% 47.29% -14.64% -94.29% -82.12% -106.11% -85.61% -11.53% -45.50% -55.72%
Free Cash Flow Firm Growth		 101.91% 204.21% 54.41% 1,994.26% -3,573.12% -278.16% -368.05% -512.74% -13.50% 77.78% 43.02%
Invested Capital Growth		 -3,497.95% -844.26% -71.33% -294.48% 0.75% 71.72% 37.46% 73.35% -66.36% -137.55% -157.55%
Revenue Q/Q Growth		 0.00% 0.00% -100.00% 0.00% -100.00% 0.00% -64.32% -21.83% -14.38% 25.33% -0.57%
EBITDA Q/Q Growth		 -16.74% 41.10% -35.02% -39.60% -46.97% 72.08% -265.69% -14.10% -29.23% 9.03% -10.33%
EBIT Q/Q Growth		 -14.97% 39.74% -19.55% -41.27% -52.85% 75.86% -330.97% -9.94% -33.45% 11.78% -12.33%
NOPAT Q/Q Growth		 -15.86% -6.49% 4.76% -14.18% -41.11% 18.70% -56.88% 3.15% -27.49% 10.04% -10.64%
Net Income Q/Q Growth		 -14.45% 20.20% 14.00% -44.91% -37.87% 30.86% -78.15% -4.03% -32.16% 11.94% -11.74%
EPS Q/Q Growth		 -10.73% 18.50% 55.14% -8.43% -27.78% 48.70% -135.59% -3.60% -31.94% 38.42% -5.13%
Operating Cash Flow Q/Q Growth		 8.01% 16.28% -32.61% -12.25% -55.90% 21.52% -50.07% -1.08% 6.32% -2.39% -60.61%
Free Cash Flow Firm Q/Q Growth		 189.23% 4,612.62% -124.10% 286.91% -263.61% -141.75% 36.69% -64.82% 55.01% 52.67% -62.34%
Invested Capital Q/Q Growth		 -46.73% -241.93% 68.88% -152.66% 63.08% 2.56% 31.19% -7.65% -130.50% -39.13% 25.40%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 100.00% 0.00% 100.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 0.00% -346.64% 0.00% -668.06% 0.00% -93.12% -954.37% -1,375.42% -2,076.09% -1,506.88% -1,671.97%
Operating Margin		 0.00% -617.60% 0.00% -686.75% 0.00% -267.57% -1,176.38% -1,457.53% -2,170.40% -1,557.87% -1,733.52%
EBIT Margin		 0.00% -362.41% 0.00% -625.81% 0.00% -78.41% -947.06% -1,331.96% -2,076.09% -1,461.28% -1,650.78%
Profit (Net Income) Margin		 0.00% -980.71% 0.00% -1,249.63% 0.00% -404.59% -2,019.99% -2,688.28% -4,149.69% -2,915.60% -3,276.60%
Tax Burden Percent		 100.08% 100.04% 174.06% 99.71% 175.74% 51.91% 99.83% 99.95% 100.08% 99.88% 99.77%
Interest Burden Percent		 204.19% 270.50% 111.84% 200.27% 102.49% 993.94% 213.66% 201.92% 199.73% 199.77% 198.95%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -511.96% -683.98% -119.05% -103.57% -102.65% -118.68% -89.77% -98.00% -111.29% -108.35% -133.40%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% -12.54% 0.00% -20.70% 0.00% -5.37% -56.98% -74.09% -133.98% -49.87% -60.96%
Return on Assets (ROA)		 0.00% -33.93% 0.00% -41.33% 0.00% -27.73% -121.53% -149.54% -267.80% -99.50% -120.99%
Return on Common Equity (ROCE)		 -511.96% -683.98% -119.05% -103.57% -102.65% -118.68% -89.77% -98.00% -111.29% -108.35% -133.40%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% -69.63% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -6.64 -7.07 -6.74 -7.69 -11 -8.82 -14 -13 -17 -15 -17
NOPAT Margin		 0.00% -432.32% 0.00% -480.73% 0.00% -187.30% -823.47% -1,020.27% -1,519.28% -1,090.51% -1,213.47%
Net Nonoperating Expense Percent (NNEP)		 -54.28% -33.77% -11.26% -15.46% -20.25% -12.27% -17.01% -16.80% -22.63% -16.43% -21.39%
Return On Investment Capital (ROIC_SIMPLE)		 -30.51% 210.19% -5.97% -6.01% -7.11% -6.20% -10.79% -12.00% -18.49% -10.42% -13.47%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 190.97% 0.00% 257.69% 0.00% 81.04% 245.87% 301.75% 316.18% 252.48% 319.90%
R&D to Revenue		 0.00% 426.63% 0.00% 429.06% 0.00% 186.52% 930.52% 1,155.78% 1,854.22% 1,305.39% 1,413.62%
Operating Expenses to Revenue		 0.00% 1,235.20% 0.00% 1,373.50% 0.00% 1,068.52% 2,352.77% 2,915.07% 4,340.80% 3,115.74% 3,467.05%
Earnings before Interest and Taxes (EBIT)		 -9.84 -5.93 -7.09 -10 -15 -3.69 -16 -18 -23 -21 -23
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -9.63 -5.67 -7.66 -11 -16 -4.39 -16 -18 -23 -21 -23
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 95.87 0.00 4.25 3.85 1.65 1.01 0.51 0.76 1.68 0.97 1.32
Price to Tangible Book Value (P/TBV)		 95.87 0.00 4.25 3.85 1.65 1.01 0.51 0.76 1.68 0.97 1.32
Price to Revenue (P/Rev)		 0.00 16.33 251.68 149.44 76.78 22.77 8.13 10.96 17.56 25.84 31.72
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 5.60 187.76 104.70 28.08 0.00 0.00 0.00 5.78 0.00 5.32
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 69.00 -0.51 0.16 0.02 0.01 0.00 0.01 0.01 0.00 0.00 0.00
Long-Term Debt to Equity		 11.61 -0.47 0.03 0.02 0.01 0.00 0.01 0.01 0.00 0.00 0.00
Financial Leverage		 -1.17 -2.04 -1.11 -1.18 -1.09 -1.23 -1.06 -1.10 -1.08 -1.08 -1.07
Leverage Ratio		 2.61 3.63 1.56 1.45 1.33 1.36 1.19 1.17 1.13 1.12 1.12
Compound Leverage Factor		 5.32 9.81 1.75 2.90 1.36 13.51 2.53 2.37 2.25 2.23 2.23
Debt to Total Capital		 98.57% -105.20% 14.02% 1.98% 1.34% 0.00% 0.94% 0.68% 0.33% 0.00% 0.00%
Short-Term Debt to Total Capital		 81.99% -8.95% 11.49% 0.06% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 16.58% -96.26% 2.53% 1.92% 1.34% 0.00% 0.94% 0.68% 0.33% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 1.43% 205.20% 85.98% 98.02% 98.66% 100.00% 99.06% 99.32% 99.67% 100.00% 100.00%
Debt to EBITDA		 -0.45 -0.09 -0.51 -0.08 -0.05 0.00 -0.03 -0.01 -0.01 0.00 0.00
Net Debt to EBITDA		 0.16 0.43 3.35 4.30 3.97 0.00 2.82 2.15 1.69 0.00 0.00
Long-Term Debt to EBITDA		 -0.08 -0.08 -0.09 -0.07 -0.05 0.00 -0.03 -0.01 -0.01 0.00 0.00
Debt to NOPAT		 -0.67 -0.11 -0.60 -0.09 -0.06 0.00 -0.03 -0.02 -0.01 0.00 0.00
Net Debt to NOPAT		 0.23 0.56 3.99 5.14 4.87 0.00 3.20 2.47 1.96 0.00 0.00
Long-Term Debt to NOPAT		 -0.11 -0.10 -0.11 -0.09 -0.06 0.00 -0.03 -0.02 -0.01 0.00 0.00
Altman Z-Score		 -16.95 -22.16 4.39 7.58 7.72 3.18 -1.14 -1.48 -1.11 0.19 0.45
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.99 0.74 4.69 6.18 13.84 12.94 11.82 9.21 6.31 8.07 7.92
Quick Ratio		 0.91 0.66 4.63 6.13 13.71 12.61 11.43 8.74 6.10 7.89 7.62
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.31 15 -3.57 6.67 -11 -26 -17 -28 -12 -5.86 -9.51
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -426,183.33%
Free Cash Flow to Firm to Interest Expense		 0.41 9.02 -4.25 10.22 -28.63 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -9.41 -3.66 -9.50 -13.72 -36.59 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -9.41 -3.66 -9.50 -13.72 -36.59 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.03 0.02 0.03 0.03 0.07 0.06 0.06 0.06 0.03 0.04
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 1.26 1.45 3.33 3.95 9.29 14.20 16.72 24.53 20.33 25.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -7.15 -24 -7.61 -19 -7.10 -6.92 -4.76 -5.13 -12 -16 -12
Invested Capital Turnover		 0.00 -0.12 -0.27 -0.27 -0.45 -0.40 -1.29 -0.63 -0.93 -0.47 -0.62
Increase / (Decrease) in Invested Capital		 -6.96 -22 -3.17 -14 0.05 18 2.85 14 -4.71 -9.52 -7.50
Enterprise Value (EV)		 22 9.16 307 339 91 -5.63 -67 -32 51 -21 28
Market Capitalization		 30 27 412 484 248 144 65 84 155 143 167
Book Value per Share		 $0.07 ($1.56) $11.67 $11.75 $12.50 $11.69 $10.39 $9.07 $7.52 $8.40 $7.12
Tangible Book Value per Share		 $0.07 ($1.56) $11.67 $11.75 $12.50 $11.69 $10.39 $9.07 $7.52 $8.40 $7.12
Total Capital		 22 -3.37 113 128 153 142 128 112 92 148 126
Total Debt		 21 3.54 16 2.53 2.05 0.00 1.21 0.76 0.31 0.00 0.00
Total Long-Term Debt		 3.61 3.24 2.86 2.46 2.05 0.00 1.21 0.76 0.31 0.00 0.00
Net Debt		 -7.47 -18 -105 -145 -158 -149 -132 -116 -104 -164 -139
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -11 -29 -12 -23 -10 -8.19 -7.33 -7.39 -14 -18 -13
Debt-free Net Working Capital (DFNWC)		 18 -8.05 109 124 149 141 126 109 91 146 125
Net Working Capital (NWC)		 -0.34 -8.35 96 124 149 141 126 109 91 146 125
Net Nonoperating Expense (NNE)		 13 8.97 7.06 12 17 10 20 22 30 26 29
Net Nonoperating Obligations (NNO)		 -7.47 -18 -105 -145 -158 -149 -132 -116 -104 -164 -139
Total Depreciation and Amortization (D&A)		 0.21 0.26 -0.57 -0.68 -0.41 -0.69 -0.12 -0.57 0.00 -0.64 -0.30
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -1,781.48% -712.73% -707.73% -320.83% -129.76% -91.74% -95.83% -155.77% -319.66% -250.92%
Debt-free Net Working Capital to Revenue		 0.00% -491.87% 6,645.96% 3,844.50% 4,612.64% 2,236.70% 1,573.32% 1,420.87% 1,024.92% 2,644.88% 2,388.65%
Net Working Capital to Revenue		 0.00% -510.27% 5,854.11% 3,842.12% 4,612.64% 2,236.70% 1,573.32% 1,420.87% 1,024.92% 2,644.88% 2,388.65%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($2.27) ($1.85) ($0.83) ($0.90) ($1.15) ($0.59) ($1.39) ($1.44) ($1.90) ($1.17) ($1.23)
Adjusted Weighted Average Basic Shares Outstanding		 4.42M 4.33M 8.31M 11.05M 12.01M 10.92M 12.20M 12.24M 12.31M 13.32M 18.71M
Adjusted Diluted Earnings per Share		 ($2.27) ($1.85) ($0.83) ($0.90) ($1.15) ($0.59) ($1.39) ($1.44) ($1.90) ($1.17) ($1.23)
Adjusted Weighted Average Diluted Shares Outstanding		 4.42M 4.33M 8.31M 11.05M 12.01M 10.92M 12.20M 12.24M 12.31M 13.32M 18.71M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($1.85) $0.00 $0.00 $0.00 ($0.59) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 4.42M 10.49M 10.69M 12.04M 12.18M 12.23M 12.24M 12.26M 17.55M 17.74M 18.53M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.64 -7.07 -6.74 -7.69 -11 -8.82 -14 -13 -17 -15 -17
Normalized NOPAT Margin		 0.00% -432.32% 0.00% -480.73% 0.00% -187.30% -823.47% -1,020.27% -1,519.28% -1,090.51% -1,213.47%
Pre Tax Income Margin		 0.00% -980.32% 0.00% -1,253.31% 0.00% -779.37% -2,023.44% -2,689.50% -4,146.49% -2,919.15% -3,284.31%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -12.90 -3.61 -8.45 -15.36 -40.17 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -8.70 -4.31 -8.03 -11.80 -28.49 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -12.90 -3.61 -8.45 -15.36 -40.17 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -8.70 -4.31 -8.03 -11.80 -28.49 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Corbus Pharmaceuticals (NASDAQ: CRBP) continues to look like a clinical-stage biotech with a strong cash position, but also one that is still burning through cash and posting meaningful losses. Based on the latest reported Q1 2026 results, the company ended the quarter with a sizable liquidity cushion, but operating performance remains heavily negative.

The big picture: CRBP has improved its balance sheet strength over the last year, largely by building cash and investment balances, while revenue has remained very small and operating losses have stayed large. For retail investors, that means the story is still centered on pipeline progress and runway, not current profitability.

  • Strong liquidity: As of Q1 2026, Corbus held $25.7 million in cash and equivalents and $112.6 million in short-term investments, for total current assets of $143.6 million.
  • Low debt burden: Total liabilities were only $18.1 million in Q1 2026, and the company reported no noncurrent liabilities, which reduces balance-sheet risk.
  • Healthy current ratio: Current assets of $143.6 million versus current liabilities of $18.1 million suggest the company has strong near-term liquidity.
  • Operating cash burn improved versus late 2024: Net cash used in operating activities was $25.6 million in Q1 2026, less severe than the near-$49.6 million operating burn seen in Q4 2025.
  • Investments continue to support runway: The company generated $22.5 million from investing activities in Q1 2026, mainly from investment maturities/sales, helping offset operating losses.
  • Revenue remains minimal: Q1 2026 revenue was just $1.4 million, which is not enough to materially cover operating expenses.
  • R&D spending remains elevated: Research and development expense was $19.8 million in Q1 2026, consistent with a development-stage biotech investing in its pipeline.
  • Other operating costs are significant: “Other operating expenses” were $24.3 million in Q1 2026, a major driver of the quarterly loss.
  • Still deeply unprofitable: Q1 2026 net loss attributable to common shareholders was $23.2 million, and diluted EPS was -$1.23.
  • Operating losses remain large: Operating loss was $24.3 million in Q1 2026, showing the business is still far from break-even.

Trend over the last several quarters: revenue has stayed in a narrow range around $1.1 million to $1.7 million per quarter, while operating expenses have generally ranged from the high teens to the high $40 millions. That mismatch keeps losses substantial. In the most recent quarter, CRBP’s loss narrowed from Q4 2025 on a revenue basis, but the company still posted a heavy operating deficit.

Share count and financing: Diluted shares outstanding were 18.7 million in Q1 2026 versus 13.3 million in Q4 2025 and 12.3 million in Q3 2025, indicating meaningful dilution over time. While the company did not issue common equity in Q1 2026, earlier quarters showed financing activity helped replenish cash. Investors should watch whether future funding needs lead to additional dilution.

Bottom line: Corbus enters 2026 with a strong balance sheet and plenty of short-term liquidity, which is a positive for a biotech company. However, the company still has very little revenue, significant operating losses, and ongoing cash burn. The stock’s next major catalyst will likely come from pipeline or clinical progress rather than financial performance alone.

07/30/26 04:57 PM ETAI Generated. May Contain Errors.

Corbus Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Corbus Pharmaceuticals' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Corbus Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$157.07 million in 2025, rising from -$8.85 million in 2015. The previous period was -$80.42 million in 2024. Check out Corbus Pharmaceuticals' forecast to explore projected trends and price targets.

Corbus Pharmaceuticals' total operating income in 2025 was -$85.31 million, based on the following breakdown:
  • Total Gross Profit: $5.53 million
  • Total Operating Expenses: $170.62 million

Over the last 10 years, Corbus Pharmaceuticals' total revenue changed from $648.38 thousand in 2015 to $5.53 million in 2025, a change of 752.9%.

Corbus Pharmaceuticals' total liabilities were at $20.69 million at the end of 2025, a 53.8% increase from 2024, and a 431.9% increase since 2015.

In the past 10 years, Corbus Pharmaceuticals' cash and equivalents has ranged from $12.34 million in 2015 to $85.43 million in 2020, and is currently $28.49 million as of their latest financial filing in 2025.

Over the last 10 years, Corbus Pharmaceuticals' book value per share changed from 0.24 in 2015 to 8.40 in 2025, a change of 3,417.5%.


Related Companies

Financial statements for NASDAQ:CRBP last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...
Banyan Hill Publishing | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
SpaceX just minted 4,400 millionaires
SpaceX's $1.75 trillion IPO turned more than 4400 employees into millionaires, according to The New York Times...
The Oxford Club | Sponsoredtc pixel
ALT SL: New Patent Reveals Elon Musk’s Next Breakthrough: M.A.G.I.
Jeff Brown and Marc Chaikin - two investors who spotted Nvidia a decade ago - are now pointing to Elon Musk's ...
Brownstone Research | Sponsoredtc pixel
Your withdrawal order could cost you in taxes
If you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...
SmartAsset | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel